Meryem Erman

The preclinical imaging platform is located in the heart of the national anticancer center Georges François Leclerc in Dijon. This center already had a great experience of clinical research (phase 1/2). The preclinical imaging platform scientific team (composed of a radiopharmacist, a pharmaco-physiologist, and a radiophysician) works in close relationships with the clinics (Oncologists, nuclear medicine MDs), offering thus a full-range translational expertise preclinical to clinical. The preclinical imaging platform enables a full approach of pharmaco-imaging, from chemistry to in vivo imaging, in a totally dedicated environment. The preclinical imaging platform offers customized services including radiolabeling, animal models development (oncology and cardiovascular diseases) and in vivo 3D imaging (Bioscan NanoSPECT®-CT / BioPET®-CT / MRS 1500TM MR solutions). In addition, the preclinical imaging platform possess strong local partnerships: * It belongs to the Pharm'Image consortium, a public-private partnership focused on pharmaco-imaging * It hosts IMAPPI project which develops of a preclinical PET-MRI prototype with the participation of Bioscan subsidiary: Bioscan Molecular Imaging France (BMIF) * More recently, the platform gathered its skills with a local company: NVH Medicinal, specialized in Engineering and biomanufacturing to offer grouped services focused on biomolecule development